Incannex Healthcare Inc (IXHL) Stock Analysis

AI analysis of Incannex Healthcare Inc (IXHL)

Sell

Incannex Healthcare Inc is not a good buy right now due to its poor financial performance and negative market sentiment. The current price is $2.24, with a 52-week high of $14.91 indicating a significant decline of 85% from its peak. The RSI is at 21.399, which suggests that the stock is oversold but also reflects a lack of buying momentum. Furthermore, the company has reported a net income loss of $24,910,000 for the last quarter, and its forward P/E ratio is 3.777, indicating potential undervaluation but also significant risk. The main risk is the negative earnings surprise of -207.69% reported in the last earnings report, which raises concerns about future profitability.

Valuation Metrics

The current forward P/E ratio for Incannex Healthcare Inc (IXHL) is 3.78, compared to its 5-year average forward P/E of -165.20.

Forward P/E

Fair

5Y Average P/E

-165.20

Current P/E

3.78

Overvalued

217.18

Undervalued

-547.58

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.64

Current EV/EBITDA

0.00

Overvalued

0.82

Undervalued

-2.09

Forward P/S

Fair

5Y Average P/S

21183.23

Current P/S

0.00

Overvalued

55744.44

Undervalued

-13377.98

Whales holding IXHL

L

L1 Capital Pty. Limited

+ HoldingIXHL

+9.12%

3M Return

IXHL FAQ — answered by Alphio AI

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Incannex Healthcare Inc is not a good buy right now due to its poor financial performance and negative market sentiment. The current price is $2.24, with a 52-week high of $14.91 indicating a significant decline of 85% from its peak. The RSI is at 21.399, which suggests that the stock is oversold but also reflects a lack of buying momentum. Furthermore, the company has reported a net income loss of $24,910,000 for the last quarter, and its forward P/E ratio is 3.777, indicating potential undervaluation but also significant risk. The main risk is the negative earnings surprise of -207.69% reported in the last earnings report, which raises concerns about future profitability.